Search

Your search keyword '"Wu, Wei‐Chi"' showing total 1,258 results
Start Over Author "Wu, Wei‐Chi"
1,258 results on '"Wu, Wei‐Chi"'

102. MicroRNA-152-3p and MicroRNA-196a-5p Are Downregulated When Müller Cells Are Promoted by Components of the Internal Limiting Membrane: Implications for Macular Hole Healing

Author

Chou, Hung-Da, primary, Shiah, Shine-Gwo, additional, Chuang, Lan-Hsin, additional, Wu, Wei-Chi, additional, Hwang, Yih-Shiou, additional, Chen, Kuan-Jen, additional, Kang, Eugene Yu-Chuan, additional, Yeung, Ling, additional, Nien, Chung-Yi, additional, and Lai, Chi-Chun, additional

Published
2023
Full Text
View/download PDF

103. Clinical Characteristics and Genetic Variants in Taiwanese Patients With PROM1-Related Inherited Retinal Disorders

Author

Lin, Tzu-Yi, primary, Wu, Pei-Liang, additional, Kang, Eugene Yu-Chuan, additional, Chi, Yi-Chun, additional, Jenny, Laura A., additional, Lin, Pei-Hsuan, additional, Lee, Chia-Ying, additional, Liu, Chun-Hsiu, additional, Liu, Laura, additional, Yeh, Lung-Kun, additional, Chen, Kuan-Jen, additional, Hwang, Yih-Shiou, additional, Wu, Wei-Chi, additional, Lai, Chi-Chun, additional, Hsiao, Meng-Chang, additional, Liu, Pei-Kang, additional, and Wang, Nan-Kai, additional

Published
2023
Full Text
View/download PDF

114. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity

Author

Nimesh A. Patel, Luis A. Acaba-Berrocal, Sandra Hoyek, Kenneth C. Fan, Maria Ana Martinez-Castellanos, Caroline R. Baumal, C. Armitage Harper, Audina M. Berrocal, Wu Wei-Chi, Rand Spencer, Shunji Kusaka, Polly Quiram, Jose Asilis, Michael P. Blair, Swati Agarwal, Anna Ells, Cagri G. Besirli, Irena Tsui, Thomas C. Lee, Aaron Nagiel, Andres Kychenthal, Jessica Kovarik, Anton Orlin, Janet Alexander, Vaidehi S. Dedania, Sengul Ozdek, Michel J. Shami, Cornelius Regan, Shilpa Desai, Moran Roni Levin, Deborah Y. Chong, Mrinali Gupta, Adam Pflugrath, Ashkan Abbey, Christopher G. Fuller, Lori E. Coors, Nicolas Yannuzzi, Catherine Negron, Hasenin Al-khersan, Paul Runge, Huseyin Baran Ozdemir, Tugce Kucukbalci, Chiharu Iwahashi, Mark Solinski, David Sutter, Jonathan Sears, Christine Sonnie, David Portney, Jake Duker, Tamara Lenis, Andreas Di-Luciano, Pablo Chamartin, Nikisha Kothari, Grecia Yael Ortiz-Ramirez, Gabriela Patricia Amadeo Oreggioni, Ameay V. Naravane, Peter J. Belin, Nahomy Ledesma Vicioso, Demetrios Vavvas, M. Elizabeth Hartnett, Robinson V.P. Chan, Eric Nudleman, Darius M. Moshfeghi, Atchara Amphornphruet, Michael Chiang, Michael J. Shapiro, J. Peter Campbell, Lejla Vajzovic, Mario Capecchi, G. Baker Hubbard, Jason Horowtiz, Rabia Karani, Rosina Negrin Martin, and Emmanuel Chang

Subjects
Ophthalmology
Published
2023
Full Text
View/download PDF

117. Presentations & factors affecting outcome of rhegmatogenous retinal detachment with choroidal detachment – An Indo-Taiwanese study

Author

Dave, Vivek Pravin, primary, Chou, Hung-Da, additional, Kiri, Hardik, additional, Ieng, Fok Chak, additional, Hwang, Yih-Shiou, additional, Wu, Wei-Chi, additional, Chen, Kuan-Jen, additional, Das, Anthony Vipin, additional, Pathengay, Avinash, additional, Pappuru, Rajeev Reddy, additional, and Lai, Chi-Chun, additional

Published
2023
Full Text
View/download PDF

118. Development of a joint set of database parameters for the EU-ROP and Fight Childhood Blindness! ROP Registries

Author

Catt, Caroline, primary, Pfeil, Johanna M, additional, Barthelmes, Daniel, additional, Gole, Glen A, additional, Krohne, Tim U, additional, Wu, Wei-Chi, additional, Kusaka, Shunji, additional, Zhao, Peiquan, additional, Dai, Shuan, additional, Elder, James, additional, Heckmann, Matthias, additional, Stack, Jacqueline, additional, Khonyongwa-Fernandez, Gigi, additional, and Stahl, Andreas, additional

Published
2023
Full Text
View/download PDF

120. Assessment of a Tele-education System to Enhance Retinopathy of Prematurity Training by International Ophthalmologists-in-Training in Mexico

Author

Chan, R.V. Paul, Jonas, Karyn E., Chiang, Michael F., Ostmo, Susan, Campbell, J. Peter, Yap, Vivien, Port, Alexander D., Patel, Samir N., Mackeen, Leslie D., Martinez-Castellanos, Maria Ana, Salinas-Longoria, Samantha, Romero, Rafael, Arriola, Andrea, Wu, Wei-Chi, Ang Sam Anzures, Rachelle Go, Ventura, Camila V., Sonmez, Kemal, Kim, Sang Jin, Jonas, Karyn, Orlin, Anton, Horowitz, Jason, Coki, Osode, Eccles, Cheryl-Ann, Sarna, Leora, Berrocal, Audina, Negron, Catherin, Denser, Kimberly, Cumming, Kristi, Osentoski, Tammy, Check, Tammy, Zajechowski, Mary, Lee, Thomas, Kruger, Evan, McGovern, Kathryn, Simmons, Charles, Murthy, Raghu, Galvis, Sharon, Rotter, Jerome, Chen, Ida, Li, Xiaohui, Taylor, Kent, Roll, Kaye, Kalpathy-Cramer, Jayashree, Erdogmus, Deniz, Ionnidis, Stratis, Olguin-Manriquez, Francisco, Meraz-Gutierrez, Miroslava, Dulanto-Reinoso, Carlos M., Montero-Mendoza, Cristina, Berrones-Medina, David, Swan, Ryan, and Ryan, Michael C.

Published
2017
Full Text
View/download PDF

125. Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity

Author

Nimesh A. Patel, Luis A. Acaba-Berrocal, Sandra Hoyek, Kenneth C. Fan, Maria Ana Martinez-Castellanos, Caroline R. Baumal, C. Armitage Harper, Audina M. Berrocal, Wu Wei-Chi, Rand Spencer, Shunji Kusaka, Polly Quiram, Jose Asilis, Michael P. Blair, Swati Agarwal, Anna Ells, Cagri G. Besirli, Irena Tsui, Thomas C. Lee, Aaron Nagiel, Andrés Kychenthal, Jessica Kovarik, Anton Orlin, Janet Alexander, Vaidehi S. Dedania, Sengul Ozdek, Michel J. Shami, Cornelius Regan, Shilpa Desai, Moran Roni Levin, Deborah Y. Chong, Mrinali Gupta, Adam Pflugrath, Ashkan Abbey, Christopher G. Fuller, Lori E. Coors, Nicolas Yannuzzi, Catherine Negron, Hasenin Al-khersan, Paul Runge, Huseyin Baran Ozdemir, Tugce Kucukbalci, Chiharu Iwahashi, Mark Solinski, David Sutter, Jonathan Sears, Christine Sonnie, David Portney, Jake Duker, Tamara Lenis, Andreas Di-Luciano, Pablo Chamartin, Nikisha Kothari, Grecia Yael Ortiz-Ramirez, Gabriela Patricia Amadeo Oreggioni, Ameay V. Naravane, Peter J. Belin, Nahomy Ledesma Vicioso, Demetrios Vavvas, M. Elizabeth Hartnett, Robinson V.P. Chan, Eric Nudleman, Darius M. Moshfeghi, Atchara Amphornphruet, Michael Chiang, and Michael J. Shapiro

Subjects
Ophthalmology
Published
2022
Full Text
View/download PDF

126. Association of sodium–glucose cotransporter‐2 inhibitors and the risk of retinal vascular occlusion: A real‐world retrospective cohort study in Taiwan.

Author

Lin, Tzu‐Yi, Kang, Eugene Yu‐Chuan, Shao, Shih‐Chieh, Lai, Edward Chia‐Cheng, Wang, Nan‐Kai, Garg, Sunir J., Chen, Kuan‐Jen, Kang, Je‐Ho, Wu, Wei‐Chi, Lai, Chi‐Chun, and Hwang, Yih‐Shiou

Subjects
CD26 antigen, COHORT analysis, ELECTRONIC health records, TRIAMCINOLONE, MACULAR edema, INTRAVITREAL injections
Abstract

Aims: Sodium–glucose cotransporter‐2 inhibitors (SGLT2is) are proposed to alleviate the development of inflammatory eye diseases. However, the association between SGLT2i and retinal vascular occlusion remains unclear. Therefore, this study aims to explore the effects of SGLT2i on the incidence of retinal vascular occlusion. Materials and Methods: This retrospective cohort study analysed electronic medical records data from the largest multi‐institutional database in Taiwan. Individuals who initiated SGLT2is and dipeptidyl peptidase 4 inhibitors (DPP4is) between 2016 and 2019 were included in our analysis. To conduct a homogenous comparison, inverse probability of treatment weighting with propensity scoring was employed. The primary outcome was retinal vascular occlusion, and the secondary outcomes were retinal vascular occlusion‐related complications (macular oedema, vitreous haemorrhage, and tractional retinal detachment) and conditions requiring vitreoretinal intervention (intravitreal injection, retinal laser therapy, and vitrectomy). Results: In total, 12,074 SGLT2i users and 39,318 DPP4i users were included. The incidence rate of retinal vascular occlusion in the SGLT2i and DPP4i groups was 1.2 (95% confidence interval [CI], 0.9–1.4) and 1.6 (95% CI, 1.3–1.8) events per 1000 person‐years, respectively, which yielded a subdistribution hazard ratio (SHR) of 0.74 (95% CI, 0.55–0.99). Similar risk reductions were observed in the retinal vascular occlusion‐related complications (SHR, 0.76; 95% CI, 0.69–0.84) and conditions requiring vitreoretinal intervention (SHR, 0.84; 95% CI, 0.77–0.94). Conclusions: In this multi‐institutional study in Taiwan, SGLT2i use was associated with a reduced risk of retinal vascular occlusion. Further prospective studies are required to ascertain this association. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

136. Real-World Effectiveness of Intravitreal Dexamethasone Implants - Comparison between Eyes Eligible and Ineligible for Clinical Trials and Their Associated Outcomes

Author

Yu-Chuan Kang, Eugene, primary, Shao, Shih-Chieh, additional, Chang, Kai-Cheng, additional, Garg, Sunir J., additional, Lin, Tzu-Yi, additional, Chen, Kuan-Jen, additional, Wu, Wei-Chi, additional, Lai, Chi-Chun, additional, Hwang, Yih-Shiou, additional, and Chia-Cheng Lai, Edward, additional

Published
2023
Full Text
View/download PDF

137. Iris-penetrated haptic of an in-bag intraocular lens with fibrotic proliferation

Author

Kang, Eugene and Wu, Wei-Chi

Subjects
Bausch & Lomb Inc., Eyewear industry, Cataract -- Surgery, Health
Abstract

Byline: Eugene. Kang, Wei-Chi. Wu Occurrence of iris penetration of an in-bag intraocular lens haptic after cataract surgery without prior history of traumatic events in a child is rare. This [...]

Published
2022

138. Immediate Sequential Bilateral Pediatric Vitreoretinal Surgery: An International Multicenter Study

Author

Yonekawa, Yoshihiro, Wu, Wei-Chi, Kusaka, Shunji, Robinson, Joshua, Tsujioka, Daishi, Kang, Kai B., Shapiro, Michael J., Padhi, Tapas R., Jain, Lubhani, Sears, Jonathan E., Kuriyan, Ajay E., Berrocal, Audina M., Quiram, Polly A., Gerber, Amanda E., Paul Chan, R.V., Jonas, Karyn E., Wong, Sui Chien, Patel, C.K., Abbey, Ashkan M., Spencer, Rand, Blair, Michael P., Chang, Emmanuel Y., Papakostas, Thanos D., Vavvas, Demetrios G., Sisk, Robert A., Ferrone, Philip J., Henderson, Robert H., Olsen, Karl R., Hartnett, M. Elizabeth, Chau, Felix Y., Mukai, Shizuo, Murray, Timothy G., Thomas, Benjamin J., Meza, P. Anthony, Drenser, Kimberly A., Trese, Michael T., and Capone, Antonio, Jr.

Published
2016
Full Text
View/download PDF

149. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Author

Lin, Tzu-Yi, Kang, Eugene Yu-Chuan, Shao, Shih-Chieh, Lai, Edward Chia-Cheng, Garg, Sunir J., Chen, Kuan-Jen, Kang, Je-Ho, Wu, Wei-Chi, Lai, Chi-Chun, Hwang, Yih-Shiou, Lin, Tzu-Yi, Kang, Eugene Yu-Chuan, Shao, Shih-Chieh, Lai, Edward Chia-Cheng, Garg, Sunir J., Chen, Kuan-Jen, Kang, Je-Ho, Wu, Wei-Chi, Lai, Chi-Chun, and Hwang, Yih-Shiou

Abstract

BACKGROUND: To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care. METHODS: This retrospective cohort study emulating a target trial included patient data from the multi-institutional Chang Gung Research Database in Taiwan. Totally, 33,021 patients with type 2 diabetes mellitus using SGLT2is and GLP1-RAs between 2016 and 2019 were identified. 3,249 patients were excluded due to missing demographics, age <40 >years, prior use of any study drug, a diagnosis of retinal disorders, a history of receiving vitreoretinal procedure, no baseline glycosylated hemoglobin, or no follow-up data. Baseline characteristics were balanced using inverse probability of treatment weighting with propensity scores. DR diagnoses and vitreoretinal interventions served as the primary outcomes. Occurrence of proliferative DR and DR receiving vitreoretinal interventions were regarded as vision-threatening DR. RESULTS: There were 21,491 SGLT2i and 1,887 GLP1-RA users included for the analysis. Patients receiving SGLT2is and GLP-1 RAs exhibited comparable rate of any DR (subdistribution hazard ratio [SHR], 0.90; 95% confidence interval [CI], 0.79 to 1.03), whereas the rate of proliferative DR (SHR, 0.53; 95% CI, 0.42 to 0.68) was significantly lower in the SGLT2i group. Also, SGLT2i users showed significantly reduced risk of composite surgical outcome (SHR, 0.58; 95% CI, 0.48 to 0.70). CONCLUSION: Compared to those taking GLP1-RAs, patients receiving SGLT2is had a lower risk of proliferative DR and vitreoretinal interventions, although the rate of any DR was comparable between the SGLT2i and GLP1-RA groups. Thus, SGLT2is may be associated with a lower risk of vision-threatening DR but not DR development.

Published
2023

150. The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients

Author

Kang, Eugene Yu-Chuan, Lin, Tzu-Yi, Garg, Sunir J., Wang, Nan-Kai, Chen, Lee-Jen, Huang, Pei-Wei, Chan, Ming-Jen, Chen, Kuan-Jen, Wu, Wei-Chi, Lai, Chi-Chun, Hwang, Yih-Shiou, Kang, Eugene Yu-Chuan, Lin, Tzu-Yi, Garg, Sunir J., Wang, Nan-Kai, Chen, Lee-Jen, Huang, Pei-Wei, Chan, Ming-Jen, Chen, Kuan-Jen, Wu, Wei-Chi, Lai, Chi-Chun, and Hwang, Yih-Shiou

Abstract

This retrospective cohort study aimed to assess the systemic effects of three commonly available anti-vascular endothelial growth factor intravitreal injections in patients with diabetes, using data taken from a multi-institutional database in Taiwan. Patient data were sourced from the multi-institutional Chang Gung Research Database. Participants were divided into groups based on treatment with bevacizumab, ranibizumab, or aflibercept. Baseline characteristics were matched among the groups by the inverse probability of treatment weighting. The incidence rate of outcome events was calculated as the number of events divided by 100 person-years of follow-up. The cumulative incidence function was used to estimate the incidence rate of the outcome events among groups. The incidence of ischemic stroke was higher in the ranibizumab group than the bevacizumab and aflibercept groups (1.65, 0.92, and 0.61 per 100 person-years, respectively). The incidence of major adverse lower-limb events was higher in the bevacizumab group (2.95), followed by ranibizumab (2.00) and aflibercept (0.74). Major bleeding was relatively higher in bevacizumab (12.1) compared to ranibizumab (4.3) and aflibercept (3.8). All-cause death was higher for both bevacizumab (3.26) and aflibercept (2.61) when compared to ranibizumab (0.55), and all-cause admission was found to be highest with bevacizumab (58.6), followed by aflibercept (30.2), and ranibizumab (27.6). The bevacizumab group demonstrated a greater decrease in glycated hemoglobin compared to the baseline level (−0.33%). However, a few differences in the clinical condition between the groups were still observed after matching. In conclusion, this study suggests that different anti-vascular endothelial growth factor agents may be associated with various and differing systemic adverse events. The differences might also be attributed to differences in patient characteristics and clinical status.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results